Bioscience

New Haven-based Trevi Therapeutics has raised more than $250 million to develop Haduvio, the only drug in development for chronic cough, with the company preparing Phase 3 trials targeting patients with idiopathic pulmonary fibrosis who cough thousands of times daily.

New Haven-based BioXcel Therapeutics has approved retention and milestone bonus agreements for senior executives following the company’s recent regulatory push to expand the use of its lead drug, IGALMI.

Veradermics Inc., the New Haven drug developer working on an oral treatment for hair loss, raised $256.3 million from its initial public offering on Wednesday.

Veradermics Inc., the New Haven drug developer working on an oral treatment for hair loss, said it expects to raise about $181.8 million in its planned initial public offering.

BioCT, the state’s life sciences industry group, is urging state lawmakers to adopt a package of tax, infrastructure and innovation policies in 2026 to help state biotech companies grow and attract talent.

Wallingford-based X9 Inc. raised nearly $13.7 million to develop an AI-guided device that uses ultrasound to help insert dialysis needles, receiving FDA approval for its ultrasound-only version in October.

BioXcel Therapeutics Inc. has named longtime biopharmaceutical executive Mark Pavao as its acting chief commercial officer, choosing an industry veteran to lead its efforts to expand the reach of its drug IGALMI.

Veradermics Inc., a New Haven-based biopharmaceutical startup developing an oral treatment for pattern hair loss, has filed for an initial public offering.

New Haven-based Biohaven Ltd. said Tuesday it expects to raise about $125 million via the sale of common shares to Janus Henderson Investors.

The company said the move is primarily aimed at addressing Nasdaq listing requirements.